Pluristem's PLX Cells May Effectively Treat Ischemic Stroke - Brain Research Journal Reports
HAIFA, Israel--(BUSINESS WIRE)--Feb 3, 2010 - Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that the results of a pre-clinical study in an animal model of ischemic stroke demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for this disorder. Results will be published in the journal Brain Research (Brain Research, Feb. 22, Vol. 1315) under the title “Transplantation of placenta-derived mesenchymal stromal cells upon experimental stroke in rats.” The study was conducted in collaboration with the Fraunhofer Institute for Immunology and Cell Therapy (IZI) in Leipzig, Germany.
The study indicates that in animals treated with PLX cells, there were significant differences to the control groups in the following parameters:
These effects occurred even though the PLX cells were administered eight and 24 hours after the inducement of the stroke. This suggests that the use of PLX cells in ischemic stroke may allow patients a longer window of time for successful treatment after the onset of the insult. Optimal current therapy dictates that patients must be treated within four and a half hours after the onset of ischemic stroke. PLX cells may increase this window from four and a half hours up to eight hours.
The authors of the study hypothesized that systematically transplanted PLX cells migrated toward the ischemic part of the brain and secreted soluble factors with considerable effects on cell death processes (apoptosis), neuron growth (neurogenesis), blood vessel growth (angiogenesis) and neuronal remodeling.
“The study's positive results suggest that PLX cells may increase the time interval for successful treatment in humans suffering from ischemic stroke, but our knowledge concerning modes of action and optimal treatment paradigms must be enlarged in further experiments before considering clinical application,” said Dr. Johannes Boltze, head of the stroke research group at The Fraunhofer Institute for IZI in Leipzig, Germany and senior author of the publication.
Zami Aberman, chairman and CEO of Pluristem, added, “This study is further evidence that PLX cells may be effective in treating various diseases including ischemic stroke.”
About Fraunhofer Institute for Cell Therapy and Immunology
The Fraunhofer Institute for Immunology and Cell Therapy (IZI) in Leipzig, Germany, founded in April 2005, is member of the Fraunhofer Life Sciences Alliance. Its objective being to find solutions to specific problems at the interfaces between medicine, life sciences and engineering for partners active in medicine-related industries and businesses. The Institute's core competencies are to be found in regenerative medicine, or more precisely in cell-therapeutic methods of regenerating non-functioning tissue and organs through to the biological substitution with tissue cultivated in vitro (tissue engineering). In order for the living organism to accept the tissues without any difficulty, it is necessary to study cellular and immunological defense and control mechanisms and take these into account during process and product development. These core competencies entail a multiplicity of tasks to be solved by new products and processes. The Institute works especially closely with hospital institutions, performing quality tests and clinical studies on their behalf. Additionally it also provides assistance in obtaining manufacturing licenses and certifications.
Pluristem is a clinical stage biotechnology company with proprietary technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem's patented and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases. See our product animation on YouTube: Animation, the content of which is not part of this press release.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when say that the study's positive results suggest that PLX cells may increase the time interval for successful treatment in humans suffering from ischemic stroke or that this study is further evidence that PLX cells may be effective in treating various diseases including ischemic stroke, we are using forward-looking statements. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
For more information visit our website at www.pluristem.com, the content of which is not part of this press release.
Contact: Pluristem Therapeutics Inc.
William Prather RPh, MD
Sr. VP Corporate Development
+ 1 212-845-4235
Posted: February 2010